Catalent (NYSE:CTLT) Posts Quarterly Earnings Results, Beats Expectations By $0.13 EPS

Catalent (NYSE:CTLT) released its quarterly earnings results on Thursday. The company reported $0.57 earnings per share for the quarter, beating the consensus estimate of $0.44 by $0.13, reports. Catalent had a negative return on equity of 2.73% and a negative net margin of 26.61%. The company had revenue of $1.30 billion for the quarter, compared to analyst estimates of $1.23 billion.

Catalent Price Performance

CTLT opened at $60.96 on Friday. The company’s 50-day simple moving average is $58.45 and its two-hundred day simple moving average is $56.96. The company has a debt-to-equity ratio of 1.37, a quick ratio of 1.77 and a current ratio of 2.51. The stock has a market capitalization of $11.03 billion, a P/E ratio of -9.99, a P/E/G ratio of 2.47 and a beta of 1.16. Catalent has a 52-week low of $31.80 and a 52-week high of $61.20.

Wall Street Analysts Forecast Growth

Several research firms have commented on CTLT. StockNews.com started coverage on Catalent in a report on Sunday, August 25th. They issued a “sell” rating on the stock. Barclays upped their price target on shares of Catalent from $47.00 to $63.00 and gave the stock an “equal weight” rating in a research note on Friday, June 28th. Finally, Royal Bank of Canada restated a “sector perform” rating and set a $63.50 price objective on shares of Catalent in a research note on Thursday, July 11th. Two analysts have rated the stock with a sell rating, six have given a hold rating and two have issued a buy rating to the company. According to MarketBeat, Catalent has a consensus rating of “Hold” and a consensus target price of $57.06.

Insider Transactions at Catalent

In other Catalent news, CEO Alessandro Maselli sold 9,088 shares of Catalent stock in a transaction that occurred on Monday, July 29th. The shares were sold at an average price of $58.76, for a total value of $534,010.88. Following the completion of the sale, the chief executive officer now owns 177,521 shares of the company’s stock, valued at approximately $10,431,133.96. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In related news, SVP Scott Gunther sold 666 shares of the business’s stock in a transaction that occurred on Friday, August 2nd. The stock was sold at an average price of $59.55, for a total transaction of $39,660.30. Following the completion of the transaction, the senior vice president now directly owns 39,635 shares in the company, valued at approximately $2,360,264.25. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Alessandro Maselli sold 9,088 shares of the firm’s stock in a transaction that occurred on Monday, July 29th. The stock was sold at an average price of $58.76, for a total transaction of $534,010.88. Following the sale, the chief executive officer now owns 177,521 shares in the company, valued at approximately $10,431,133.96. The disclosure for this sale can be found here. Insiders sold 14,810 shares of company stock worth $858,941 over the last three months. 0.31% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of CTLT. Dimensional Fund Advisors LP grew its holdings in Catalent by 29.9% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,639,197 shares of the company’s stock valued at $73,655,000 after buying an additional 376,931 shares in the last quarter. UBS Group AG lifted its holdings in shares of Catalent by 2.6% in the 4th quarter. UBS Group AG now owns 726,563 shares of the company’s stock worth $32,644,000 after acquiring an additional 18,752 shares during the last quarter. Gamco Investors INC. ET AL lifted its stake in shares of Catalent by 403.3% during the 1st quarter. Gamco Investors INC. ET AL now owns 25,300 shares of the company’s stock worth $1,428,000 after acquiring an additional 20,273 shares during the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its stake in shares of Catalent by 2,792.9% during the first quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 516,390 shares of the company’s stock valued at $29,150,000 after purchasing an additional 498,540 shares during the period. Finally, UniSuper Management Pty Ltd grew its stake in Catalent by 509.4% in the 1st quarter. UniSuper Management Pty Ltd now owns 18,204 shares of the company’s stock worth $1,028,000 after acquiring an additional 15,217 shares in the last quarter.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.